US20010028879A1 - Inhibition of graft versus host disease - Google Patents
Inhibition of graft versus host disease Download PDFInfo
- Publication number
- US20010028879A1 US20010028879A1 US09/853,755 US85375501A US2001028879A1 US 20010028879 A1 US20010028879 A1 US 20010028879A1 US 85375501 A US85375501 A US 85375501A US 2001028879 A1 US2001028879 A1 US 2001028879A1
- Authority
- US
- United States
- Prior art keywords
- cells
- oxidative stress
- cell
- ozone
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title claims abstract description 30
- 208000024908 graft versus host disease Diseases 0.000 title claims abstract description 30
- 230000005764 inhibitory process Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 55
- 210000004027 cell Anatomy 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 38
- 230000036542 oxidative stress Effects 0.000 claims abstract description 35
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 21
- 239000000725 suspension Substances 0.000 claims abstract description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001301 oxygen Substances 0.000 claims abstract description 14
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 14
- 230000016396 cytokine production Effects 0.000 claims abstract description 13
- 230000009696 proliferative response Effects 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 239000008246 gaseous mixture Substances 0.000 claims abstract description 3
- 210000000130 stem cell Anatomy 0.000 claims description 27
- 230000005855 radiation Effects 0.000 claims description 20
- 239000007800 oxidant agent Substances 0.000 claims description 12
- 239000007789 gas Substances 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 7
- 229910001882 dioxygen Inorganic materials 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000010322 bone marrow transplantation Methods 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 208000015322 bone marrow disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 12
- 210000001185 bone marrow Anatomy 0.000 abstract description 11
- 230000005587 bubbling Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000015215 Stem Cell Factor Human genes 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000329 lymphopenic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Definitions
- This invention relates to cellular compositions useful in medical treatments, processes for their preparation and their uses in medical treatments. More specifically, it relates to cellular compositions useful in alleviation of complications following allogeneic bone marrow transplantation, namely graft versus host disease in mammalian patients, especially in human patients, and to processes for preparation of such compositions of matter.
- Bone marrow transplantation is indicated following a process which destroys bone marrow.
- bone marrow is the first target to fail.
- Metastatic cancers are commonly treated with very intensive chemotherapy, which is intended to destroy the cancer, but also effectively destroys the bone marrow.
- Leukemia is a bone marrow malignancy, which is often treated with BMT after chemotherapy and/or radiation has been utilized to eradicate malignant cells.
- BMT is currently used for treatment of leukemias which are life-threatening.
- Some autoimmune diseases may be severe enough to require obliteration of their native immune systems which includes concomitant bone marrow obliteration and requires subsequent bone marrow transplantation. Alleviation of any but the most acute life-threatening conditions involving bone marrow disorders with BMT is, however, generally regarded as too risky, because of the likelihood of the onset of graft versus host disease.
- GVHD graft-versus-host disease
- allo-BMT allogeneic bone marrow or stem cell transplantation
- GVHD is caused by donor T-cells reacting against systemically distributed incompatible host antigens, causing powerful inflammation.
- mature donor T-cells that recognize differences between donor and host become systemically activated.
- Current methods to prevent and treat GVHD involve administration of drugs such as cyclosporin-A and corticosteroids. These have serious side effects, must be given for prolonged periods of time, and are expensive to administer and to monitor. Attempts have also been made to use T-cell depletion to prevent GVHD, but this requires sophisticated and expensive facilities and expertise. Too great a degree of T-cell depletion leads to serious problems of failure of engraftment of bone marrow stem cells, failure of hematopoietic reconstitution, infections, or relapse. More limited T-cell depletion leaves behind cells that are still competent to initiate GVHD. As a result, current methods of treating GVHD are only successful in limited donor and host combinations, so that many patients cannot be offered potentially life-saving treatment.
- a patient being treated by allo-BMT is administered a composition containing T-cells obtained from an allogeneic donor, said T-cells having been subjected in vitro to oxidative stress to induce therein decreased inflammatory cytokine production coupled with reduced proliferative response.
- oxidatively stressed allogeneic T-cells when injected into a mammalian patient, have a down-regulated immune response and a down-regulated destructive allogeneic response against the recipient, so that engraftment of the hematopoietic stem cells, administered along with or separately from the stressed T-cells, can take effect with significantly reduced risk of development of GVHD.
- the population of stressed T-cells nevertheless appears to be able to exert a sufficient protective effect on the mammalian system to guard against failure of engraftment and against infection, whilst the hematopoietic system is undergoing reconstitution, at least in part, by proliferation and differentiation of the allogeneic stem cells.
- One aspect of the present invention provides, accordingly, a process of treating a mammalian patient for alleviation of a bone marrow mediated disease, with alleviation of consequently developed graft versus host disease (GVHD), which comprises administering to the patient allogeneic hematopoietic stem cells and allogeneic T-cells, at least a portion of said T-cells having been subjected to oxidative stress in vitro, prior to administration to the patient, so as to induce an altered cytokine production profile and a reduced proliferative response therein.
- GVHD graft versus host disease
- Another aspect of the present invention provides a population of mammalian T-cells, essentially free of stem cells, said T-cells having been subjected in vitro to oxidative stress so as to induce in said cells an altered cytokine production profile and a reduced proliferative response.
- a further aspect of the present invention provides a process for preparing an allogeneic cell population for administration to a human patient suffering from a bone marrow mediated disease, which comprises subjecting, in vitro, a population of donor cells enriched in T-cells to oxidative stress to induce in said T-cells an altered cytokine production profile and a reduced proliferative response.
- FIGS. 1 and 2 of the accompanying drawings are graphical presentations of results obtained according to Example 3 below.
- FIG. 3 is a depiction of the results obtained from Example 4 below.
- the process of the present invention involves an initial collection of hematopoietic stem cells and T-cells from a donor.
- the preferred source of such cells is mobilized stem cells and T-cells from the peripheral blood of the donor.
- Stem cells are present in very small quantities in peripheral blood, and one preferred way of operating in accordance with the invention is to enrich the stem cell population of the donor's peripheral blood, and then to extract the donor's peripheral blood for use as a source of stem cells and T-cells for treatment as described and subsequent injection into the patient. Enrichment may be achieved by giving the donor a course of injections of appropriate growth factors, over several days e.g. five days prior to extracting peripheral blood from the donor.
- Appropriate cell fractions can be collected from the blood by leukopheresis, a known procedure, as it is extracted, with the plasma and red cells being returned to the donor, in a closed flow system.
- the white cell collection which contains the stem cells (about 3%) and T-cells (about 40%) along with B-cells, neutrophils and other white cells, may be treated to alter their cytokine production profiles and to reduce the proliferative response of the T-cells therein, and then administered to the host patient, in accordance with the invention, as a whole collection of cells (peripheral blood mononuclear cells).
- the donor T-cells are separated from the other cells, so that only the T-cells are subjected to oxidative stress and then administered to the patient, with the stem cells for engraftment being administered to the patient separately from the treated T-cells.
- the stem cells for engraftment being administered to the patient separately from the treated T-cells.
- subjection of the collection of peripheral blood mononuclear cells to the stressors is satisfactory, without further fractionation to isolate the T-cells, which is a difficult and expensive procedure.
- Separate administration of stem cells is strongly preferred.
- whole bone marrow of the donor can be used as the source of T-cells and stem cells for the process of the invention.
- Whole bone marrow has in the past been the usual source of cells for allogeneic cell transplantation procedures, and can indeed be used in the present process. It is however an inconvenient and uncomfortable procedure for the donor, requiring anaesthetic and lengthy extraction procedures.
- Any source of T-cells and stem cells from the donor can be used in principle, but peripheral blood enriched in stem cells and T-cells is the most clinically convenient.
- the alteration in cytokine production profile induced in the T-cells in the process of the invention is preferably a reduction in production of inflammatory cytokines, such as interferon- ⁇ and tissue necrosis factor- ⁇ .
- the oxidative stress may be applied to the T-cells by subjecting them to an oxidative environment such as the addition of a gaseous, liquid or solid chemical oxidizing agent (ozone, molecular oxygen, ozone/oxygen gas mixtures, permanganates, periodates, peroxides, drugs acting on biological systems through an oxidative mechanism such as adriamycin, and the like).
- a gaseous, liquid or solid chemical oxidizing agent ozone, molecular oxygen, ozone/oxygen gas mixtures, permanganates, periodates, peroxides, drugs acting on biological systems through an oxidative mechanism such as adriamycin, and the like.
- a gaseous oxidizing agent such as an ozone/oxygen gas mixture bubbled through the suspension of cells, optionally in combination with the simultaneous subjection of the cells to ultraviolet radiation, in appropriate doses.
- One method according to the present invention subjects the allogeneic white cells from the donor, including both the stem cells and the T-cells, to oxidative stress.
- This eliminates the need to include a complicated and costly step of separating the T-cells from the other cellular components of the white cells composition.
- This can be accomplished by including one or more stem cell growth factors in the cell composition at the time of subjecting it to the stress. Protection of the stem cells from the deleterious effects of the oxidative stress is achieved by the presence of growth factors, and so, prior to subjecting the stem cell-T-cell composition to oxidative stress, one or more stem cell growth factors are added to the composition.
- Stem cell growth factors useful in the process are cytokines which promote survival of stem cells (but not T-cells) during this stressing. They are cytokines which interact with growth receptors on stem cells. They are believed to activate the MAP-kinase pathway of the cell, resulting in the activation of erk. Examples of suitable such growth factors, include stem cell specific growth factors, kit-ligand, IL-3, GM-CSF and FLT 3 ligand, all of which are known. It is preferred to add precise amounts of extracted, purified growth factors or, especially, recombinant growth factors available on the market, or combinations thereof, suitably dissolved or suspended in appropriate, biologically acceptable fluids.
- One preferred method of subjecting the allogeneic T-cells to oxidative stress involves exposing a suspension of the cells to a mixture of medical grade oxygen and ozone gas, for example by bubbling through the suspension a stream of medical grade oxygen gas having ozone as a minor component therein.
- the suspending medium may be any of the commonly used biologically acceptable media which maintains cells in viable condition.
- the ozone gas may be provided by any conventional source known in the art.
- the gas stream has an ozone content of from about 1.0-100 ⁇ g/ml, preferably 3-70 ⁇ g/ml and most preferably from about 5-50 ⁇ g/ml.
- the gas stream is supplied to the aliquot at a rate of from about 0.01-2 liters per minute, preferably 0.05-1.0 liters per minute, and most preferably at about 0.06-0.30 liters per minute (STP).
- Another method of subjecting the T-cells to oxidative stress to render them suitable for use in the present invention is to add to a suspension of the cells a chemical oxidant of appropriate biological acceptability, and in biologically acceptable amounts.
- a chemical oxidant of appropriate biological acceptability, and in biologically acceptable amounts.
- Permanganates, periodates and peroxides are suitable, when used in appropriate quantities.
- Hydrogen peroxide is useful in demonstrating the effectiveness of the process of the invention and in giving guidance on the appropriate quantity of oxidizing agent to be used, although it is not an agent of first choice for the present invention, for practical reasons.
- a suitable amount of oxidizing agent is hydrogen peroxide in a concentration of from 1 micromolar ⁇ 2 millimolar, contacting a 10 ml suspension containing from 10-6 to 10-8 cells per ml, for 20 minutes, or equivalent oxidative stress derived from a different oxidizing agent.
- Optimum is about 1 millimolar hydrogen peroxide in such a suspension for about 20 minutes, or the equivalent of another oxidizing agent calculated to give a corresponding degree of oxidative stress to the cells.
- the size of the cell suspension to be subjected to oxidative stress is generally from about 0.1 ml to about 1000 ml, preferably from about 1-500, and containing appropriate numbers of T-cells for subsequent administration to a patient undergoing allo-BMT. These numbers generally correspond to those used in prior methods of allogeneic T-cell administration in connection with allo-BMT, and are familiar to those skilled in the art.
- One specific process according to the invention is to subject the cell suspension simultaneously to oxygen/ozone bubbled through the suspension and ultraviolet radiation. This also effects the appropriate changes in the nature of the T-cells. Care must be taken not to utilize an excessive dosage of oxygen/ozone or UV, to the extent that the cell membranes are caused to be disrupted, or other irreversible damage is caused to an excessive number of the cells.
- the temperature at which the T-cell suspension is subjected to the oxidative stress does not appear to be critical, provided that it keeps the suspension in the liquid phase and is not so high that it causes cell membrane disruption.
- the temperature should not be higher than about 45° C.
- ultraviolet radiation When ultraviolet radiation is used in conjunction with the oxygen/ozone oxidative stressor, it is suitably applied by irradiating the suspension under treatment from an appropriate source of UV radiation, while the aliquot is maintained at the aforementioned temperature and while the oxygen/ozone gaseous mixture is being bubbled through the aliquot.
- the ultraviolet radiation may be provided by any conventional source known in the art, for example by a plurality of low-pressure ultraviolet lamps.
- a standard UV-C source of ultraviolet radiation namely UV lamps emitting primarily in the C-band wavelengths, i.e. at wavelengths shorter than about 280 nm.
- UV-C source of ultraviolet radiation namely UV lamps emitting primarily in the C-band wavelengths, i.e. at wavelengths shorter than about 280 nm.
- UV-A and UV-B sources can also be used.
- UV radiation Preferably employed are low-pressure ultraviolet lamps that generate a line spectrum wherein at least 90% of the radiation has a wavelength of about 254 nm.
- Each such lamp provides an intensity, at a distance of 1 metre, of from about 40-80 micro wafts per square centimeter.
- Several such samples surrounding the sample container, with a combined output at about 254 nm of 15-40 watts, preferably 20-40 wafts, operated at maximum intensity may advantageously be used.
- the UV energy supplied may be from about 0.25-4.5 j/cm 2 during a 3-minute exposure, preferably 0.9-1.8 j/cm 2 .
- Such a treatment provides a suspension aliquot which is appropriately modified according to the invention ready for injection into the patient.
- the time for which the aliquot is subjected to the stressors can be from a few seconds to about 60 minutes. It is normally within the time range of from about 0.5-60 minutes. This depends to some extent upon the chosen intensity of the UV irradiation, the temperature and the concentration of and rate at which the oxidizing agent is supplied to the aliquot. Some experimentation to establish optimum times and dosages may be necessary on the part of the operator, once the other stressor levels have been set. Under most stressor conditions, preferred times will be in the approximate range of about 0.5-10 minutes, most preferably 2-5 minutes, and normally around 3 minutes.
- the suspension of cells may be treated with oxygen/ozone gas mixture and optionally also with UV radiation using an apparatus of the type described in U.S. Pat. No. 4,968,483 Mueller.
- the suspension is placed in a suitable, sterile, UV-radiation-transmissive container, which is then fitted into the machine.
- the temperature of the aliquot is adjusted to the predetermined value, e.g. 42.5 ⁇ 1 C, by the use of a suitable heat source such as an IR lamp, and the UV lamps are switched on for a fixed period before the gas flow is applied to the aliquot providing the oxidative stress, to allow the output of the UV lamps to stabilize.
- the oxygen/ozone gas mixture of known composition and control flow rate, is applied to the aliquot, for the predetermined duration of 0.5-60 minutes, preferably 1-5 minutes and most preferably about 3 minutes as discussed above.
- the suspension is appropriately modified according to the present invention sufficient to achieve the desired effects of alleviation or prevention of GVHD.
- the preferred embodiment of the present invention may be viewed as a process of treating allogeneic T-cells prior to their introduction into a patient, by extracorporeally stressing the T-cells, which comprises subjecting the T-cells to oxidative stress such as exposure to ozone or ozone/oxygen.
- the treated allogeneic T-cells from the process of the invention have a direct effect on the development and progression of GVHD.
- the donor T-cells pretreated according to the process of the invention prior to introduction into the host patient have been modified, so that they no longer mount a deleterious response. Their ability to mount an inflammatory cytokine response has been decreased.
- the spleen of a mammal offers a convenient, accessible source of cells, especially T-cells but also including small quantities of stem cells and is particularly useful in connection with animal models for experimental purposes.
- mice T-cells from C57B1/6J (B6) mice were intravenously injected into sub-lethally irradiated CB-17 SCID mice.
- the latter are congenitally lymphopenic and provide a strong stimulus for donor cells due to their complete disparity at the major histocompatibility locus (MHC).
- MHC major histocompatibility locus
- GVHD is characterized by suppression of host hematopoietic recovery from irradiation; expansion of T-cells that use V ⁇ 3 chain to form their T-cell receptor complexes (TCR's); spontaneous secretion of interferon- ⁇ and TNF- ⁇ , by donor T-cells, and aberrant localization of donor T-cells to the red pulp areas of the spleen. If donor marrow is co-injected with T-cells, a chronic form of GVHD results.
- FCS fetal calf serum
- Example 1 The experiment of Example 1 was essentially repeated except that the cells were suspended in 100% FCS. The immediate survival of the cells in this case was 50-60%, indicating that factors present in the FCS have exerted a protective effect on at least some of the cells.
- Murine B6 spleen cells suspended in 100% FCS were subjected to UV-oxidation-heat treatment
- the cell suspension was subjected simultaneously to ultraviolet radiation from UV-C lamps, wavelength 253.7 nm, whilst bubbling through the suspension a gas mixture of 14-15 mcg/ml ozone/medical grade oxygen, at 42.5° C.
- the treatment took place for 3 minutes.
- Varying numbers were injected into sub-lethally irradiated CB-17 SCID mice. Their subsequent behaviour was compared with similar numbers of B6 spleen cells, not subjected to the treatment.
- FIG. 1 is a graphical presentation of the results of these experiments, where the % survival of the animals in each group is plotted as ordinate against days following injection of the treated or untreated cells. At all dosage levels, there is a marked improvement of survival when the treated cells are used as opposed to the untreated cells, demonstrating potential for the process of the invention in alleviating GVHD.
- FIG. 2 of the accompanying drawings is a plot of the number of donor T-cells per spleen against days after GVHD induction, in these same experiments. This shows that the treated donor T-cells survive and expand in number in the host mice, although to a more limited degree than control, untreated B6 T-cells.
- FIG. 3 of the accompanying drawings The results were assessed by intracellular flow cytometry, and the results thereof are depicted in FIG. 3 of the accompanying drawings.
- the percentage of each cells in each quadrant is recorded.
- TNF tissue necrosis factor- ⁇
- the initial CD4/CD8 ratios of 1.3 ⁇ 0.2 and 2.2 ⁇ 0.3 decreased to 0.33 ⁇ 0.05 and 0.9 ⁇ 0.1 by day 13 for unstressed B6 and C3H donor T cells, respectively, at a time when many animals were succumbing to GVHD.
- the ratios remained greater than 1 at all times and correlated with the lack of clinical evidence of GVHD when donor cells had been pretreated with the stressors as described in Example 1.
- PBMCs Peripheral human blood mononuclear cells
- PHA phytohaemagglutinin
- H 2 O 2 survival % % response 7-day Profile 100 ⁇ mole/L 80-90 100 2000 + IFN ⁇ 300 ⁇ moIe/L 80-90 50 2000 + IFN ⁇ 1 mmole/L 80-90 40 400 + IFN ⁇ 3 mmole/L 80-90 40 400 + IFN ⁇ Control 95 95 8575 + IFN ⁇
Abstract
The development of graft versus host disease in a mammalian patient undergoing cell transplantation therapy for treatment of a bone marrow mediated disease, is prevented or alleviated by subjecting at least the T-cells of the allogeneic cell transplantation composition, extracorporeally, to oxidative stress, in appropriate dosage amounts, such as bubbling a gaseous mixture of ozone and oxygen through a suspension of the T-cells. The process may also include irradiation of the cells with UV light, simultaneously with the application of the oxidative stress. The oxidative stress induces reduced inflammatory cytokine production and a reduced proliferative response in the T-cells.
Description
-
- This invention relates to cellular compositions useful in medical treatments, processes for their preparation and their uses in medical treatments. More specifically, it relates to cellular compositions useful in alleviation of complications following allogeneic bone marrow transplantation, namely graft versus host disease in mammalian patients, especially in human patients, and to processes for preparation of such compositions of matter.
- Bone marrow transplantation, BMT, is indicated following a process which destroys bone marrow. For example, following intensive systemic radiation or chemotherapy, bone marrow is the first target to fail. Metastatic cancers are commonly treated with very intensive chemotherapy, which is intended to destroy the cancer, but also effectively destroys the bone marrow. This induces a need for BMT. Leukemia is a bone marrow malignancy, which is often treated with BMT after chemotherapy and/or radiation has been utilized to eradicate malignant cells. BMT is currently used for treatment of leukemias which are life-threatening. Some autoimmune diseases may be severe enough to require obliteration of their native immune systems which includes concomitant bone marrow obliteration and requires subsequent bone marrow transplantation. Alleviation of any but the most acute life-threatening conditions involving bone marrow disorders with BMT is, however, generally regarded as too risky, because of the likelihood of the onset of graft versus host disease.
- Graft-versus-host disease, GVHD, is an immunological disorder that is the major factor that limits the success and availability of allogeneic bone marrow or stem cell transplantation (collective referred to herein as allo-BMT) for treating some forms of otherwise incurable hematological malignancies, such as leukemia. GVHD is a systemic inflammatory reaction which causes chronic illness and may lead to death of the host mammal. At present, allogeneic transplants invariably run a severe risk of associated GVHD, even where the donor has a high degree of histocompatibility with the host.
- GVHD is caused by donor T-cells reacting against systemically distributed incompatible host antigens, causing powerful inflammation. In GVHD, mature donor T-cells that recognize differences between donor and host become systemically activated. Current methods to prevent and treat GVHD involve administration of drugs such as cyclosporin-A and corticosteroids. These have serious side effects, must be given for prolonged periods of time, and are expensive to administer and to monitor. Attempts have also been made to use T-cell depletion to prevent GVHD, but this requires sophisticated and expensive facilities and expertise. Too great a degree of T-cell depletion leads to serious problems of failure of engraftment of bone marrow stem cells, failure of hematopoietic reconstitution, infections, or relapse. More limited T-cell depletion leaves behind cells that are still competent to initiate GVHD. As a result, current methods of treating GVHD are only successful in limited donor and host combinations, so that many patients cannot be offered potentially life-saving treatment.
- International Patent Application No. PCT/CA97/00564 Bolton describes an autovaccine for alleviating the symptoms of an autoimmune disease in a mammalian patient, comprising an aliquot of modified blood obtained from the same patient and treated extracorporeally with ultraviolet radiation and an oxygen/ozone gas mixture bubbled therethrough, at an elevated temperature (42.5° C.), the autovaccine being re-administered to the same patient after having been so treated.
- It is an object of the present invention to provide a process of alleviating the development of GVHD complications in a mammalian patient undergoing allo-BMT procedures.
- According to the present invention, a patient being treated by allo-BMT is administered a composition containing T-cells obtained from an allogeneic donor, said T-cells having been subjected in vitro to oxidative stress to induce therein decreased inflammatory cytokine production coupled with reduced proliferative response. It appears that such oxidatively stressed allogeneic T-cells when injected into a mammalian patient, have a down-regulated immune response and a down-regulated destructive allogeneic response against the recipient, so that engraftment of the hematopoietic stem cells, administered along with or separately from the stressed T-cells, can take effect with significantly reduced risk of development of GVHD. The population of stressed T-cells nevertheless appears to be able to exert a sufficient protective effect on the mammalian system to guard against failure of engraftment and against infection, whilst the hematopoietic system is undergoing reconstitution, at least in part, by proliferation and differentiation of the allogeneic stem cells.
- One aspect of the present invention provides, accordingly, a process of treating a mammalian patient for alleviation of a bone marrow mediated disease, with alleviation of consequently developed graft versus host disease (GVHD), which comprises administering to the patient allogeneic hematopoietic stem cells and allogeneic T-cells, at least a portion of said T-cells having been subjected to oxidative stress in vitro, prior to administration to the patient, so as to induce an altered cytokine production profile and a reduced proliferative response therein.
- Another aspect of the present invention provides a population of mammalian T-cells, essentially free of stem cells, said T-cells having been subjected in vitro to oxidative stress so as to induce in said cells an altered cytokine production profile and a reduced proliferative response.
- A further aspect of the present invention provides a process for preparing an allogeneic cell population for administration to a human patient suffering from a bone marrow mediated disease, which comprises subjecting, in vitro, a population of donor cells enriched in T-cells to oxidative stress to induce in said T-cells an altered cytokine production profile and a reduced proliferative response.
- FIGS. 1 and 2 of the accompanying drawings are graphical presentations of results obtained according to Example 3 below.
- FIG. 3 is a depiction of the results obtained from Example 4 below.
- The process of the present invention involves an initial collection of hematopoietic stem cells and T-cells from a donor. The preferred source of such cells is mobilized stem cells and T-cells from the peripheral blood of the donor. Stem cells are present in very small quantities in peripheral blood, and one preferred way of operating in accordance with the invention is to enrich the stem cell population of the donor's peripheral blood, and then to extract the donor's peripheral blood for use as a source of stem cells and T-cells for treatment as described and subsequent injection into the patient. Enrichment may be achieved by giving the donor a course of injections of appropriate growth factors, over several days e.g. five days prior to extracting peripheral blood from the donor. Appropriate cell fractions can be collected from the blood by leukopheresis, a known procedure, as it is extracted, with the plasma and red cells being returned to the donor, in a closed flow system. The white cell collection, which contains the stem cells (about 3%) and T-cells (about 40%) along with B-cells, neutrophils and other white cells, may be treated to alter their cytokine production profiles and to reduce the proliferative response of the T-cells therein, and then administered to the host patient, in accordance with the invention, as a whole collection of cells (peripheral blood mononuclear cells). Preferably, however, the donor T-cells are separated from the other cells, so that only the T-cells are subjected to oxidative stress and then administered to the patient, with the stem cells for engraftment being administered to the patient separately from the treated T-cells. For practical purposes, however, subjection of the collection of peripheral blood mononuclear cells to the stressors is satisfactory, without further fractionation to isolate the T-cells, which is a difficult and expensive procedure. Separate administration of stem cells is strongly preferred.
- If for some reason it is desired to subject the entire white cell collection to oxidative stress to induce the aforementioned changes in the T-cell portion thereof, and then administer the entire collection to the patient, it is preferred to protect the stem cells from any damaging effects of the oxidative stress in a manner described below.
- In an alternative, but less preferred, procedure, whole bone marrow of the donor can be used as the source of T-cells and stem cells for the process of the invention. Whole bone marrow has in the past been the usual source of cells for allogeneic cell transplantation procedures, and can indeed be used in the present process. It is however an inconvenient and uncomfortable procedure for the donor, requiring anaesthetic and lengthy extraction procedures. Any source of T-cells and stem cells from the donor can be used in principle, but peripheral blood enriched in stem cells and T-cells is the most clinically convenient.
- The alteration in cytokine production profile induced in the T-cells in the process of the invention is preferably a reduction in production of inflammatory cytokines, such as interferon-γ and tissue necrosis factor-α.
- The oxidative stress may be applied to the T-cells by subjecting them to an oxidative environment such as the addition of a gaseous, liquid or solid chemical oxidizing agent (ozone, molecular oxygen, ozone/oxygen gas mixtures, permanganates, periodates, peroxides, drugs acting on biological systems through an oxidative mechanism such as adriamycin, and the like). In one preferred method according to the invention, the T-cells are subjected, in suspension, to a gaseous oxidizing agent, such as an ozone/oxygen gas mixture bubbled through the suspension of cells, optionally in combination with the simultaneous subjection of the cells to ultraviolet radiation, in appropriate doses.
- One method according to the present invention subjects the allogeneic white cells from the donor, including both the stem cells and the T-cells, to oxidative stress. This eliminates the need to include a complicated and costly step of separating the T-cells from the other cellular components of the white cells composition. In such case, however, it is strongly preferred to protect the stem cells in the composition from deleterious effects of the stress. This can be accomplished by including one or more stem cell growth factors in the cell composition at the time of subjecting it to the stress. Protection of the stem cells from the deleterious effects of the oxidative stress is achieved by the presence of growth factors, and so, prior to subjecting the stem cell-T-cell composition to oxidative stress, one or more stem cell growth factors are added to the composition. Stem cell growth factors useful in the process are cytokines which promote survival of stem cells (but not T-cells) during this stressing. They are cytokines which interact with growth receptors on stem cells. They are believed to activate the MAP-kinase pathway of the cell, resulting in the activation of erk. Examples of suitable such growth factors, include stem cell specific growth factors, kit-ligand, IL-3, GM-CSF and
FLT 3 ligand, all of which are known. It is preferred to add precise amounts of extracted, purified growth factors or, especially, recombinant growth factors available on the market, or combinations thereof, suitably dissolved or suspended in appropriate, biologically acceptable fluids. - One preferred method of subjecting the allogeneic T-cells to oxidative stress according to the invention involves exposing a suspension of the cells to a mixture of medical grade oxygen and ozone gas, for example by bubbling through the suspension a stream of medical grade oxygen gas having ozone as a minor component therein. The suspending medium may be any of the commonly used biologically acceptable media which maintains cells in viable condition. The ozone gas may be provided by any conventional source known in the art. Suitably the gas stream has an ozone content of from about 1.0-100 μg/ml, preferably 3-70 μg/ml and most preferably from about 5-50 μg/ml. The gas stream is supplied to the aliquot at a rate of from about 0.01-2 liters per minute, preferably 0.05-1.0 liters per minute, and most preferably at about 0.06-0.30 liters per minute (STP).
- Another method of subjecting the T-cells to oxidative stress to render them suitable for use in the present invention is to add to a suspension of the cells a chemical oxidant of appropriate biological acceptability, and in biologically acceptable amounts. Permanganates, periodates and peroxides are suitable, when used in appropriate quantities. Hydrogen peroxide is useful in demonstrating the effectiveness of the process of the invention and in giving guidance on the appropriate quantity of oxidizing agent to be used, although it is not an agent of first choice for the present invention, for practical reasons. Thus, a suitable amount of oxidizing agent is hydrogen peroxide in a concentration of from 1 micromolar −2 millimolar, contacting a 10 ml suspension containing from 10-6 to 10-8 cells per ml, for 20 minutes, or equivalent oxidative stress derived from a different oxidizing agent. Optimum is about 1 millimolar hydrogen peroxide in such a suspension for about 20 minutes, or the equivalent of another oxidizing agent calculated to give a corresponding degree of oxidative stress to the cells.
- The size of the cell suspension to be subjected to oxidative stress is generally from about 0.1 ml to about 1000 ml, preferably from about 1-500, and containing appropriate numbers of T-cells for subsequent administration to a patient undergoing allo-BMT. These numbers generally correspond to those used in prior methods of allogeneic T-cell administration in connection with allo-BMT, and are familiar to those skilled in the art.
- One specific process according to the invention is to subject the cell suspension simultaneously to oxygen/ozone bubbled through the suspension and ultraviolet radiation. This also effects the appropriate changes in the nature of the T-cells. Care must be taken not to utilize an excessive dosage of oxygen/ozone or UV, to the extent that the cell membranes are caused to be disrupted, or other irreversible damage is caused to an excessive number of the cells.
- The temperature at which the T-cell suspension is subjected to the oxidative stress does not appear to be critical, provided that it keeps the suspension in the liquid phase and is not so high that it causes cell membrane disruption. The temperature should not be higher than about 45° C.
- When ultraviolet radiation is used in conjunction with the oxygen/ozone oxidative stressor, it is suitably applied by irradiating the suspension under treatment from an appropriate source of UV radiation, while the aliquot is maintained at the aforementioned temperature and while the oxygen/ozone gaseous mixture is being bubbled through the aliquot. The ultraviolet radiation may be provided by any conventional source known in the art, for example by a plurality of low-pressure ultraviolet lamps. There is preferably used a standard UV-C source of ultraviolet radiation, namely UV lamps emitting primarily in the C-band wavelengths, i.e. at wavelengths shorter than about 280 nm. Ultraviolet radiation corresponding to standard UV-A and UV-B sources can also be used. Preferably employed are low-pressure ultraviolet lamps that generate a line spectrum wherein at least 90% of the radiation has a wavelength of about 254 nm. An appropriate dosage of such UV radiation, applied simultaneously with the aforementioned temperature and oxidative environment stressors, is obtained from lamps with a power output of from about 5 to about 25 wafts, preferably about 5 to about 10 watts, at the chosen UV wavelength, arranged to surround the sample container holding the aliquot. Each such lamp provides an intensity, at a distance of 1 metre, of from about 40-80 micro wafts per square centimeter. Several such samples surrounding the sample container, with a combined output at about 254 nm of 15-40 watts, preferably 20-40 wafts, operated at maximum intensity may advantageously be used. At the incident surface of the aliquot, the UV energy supplied may be from about 0.25-4.5 j/cm2 during a 3-minute exposure, preferably 0.9-1.8 j/cm2. Such a treatment provides a suspension aliquot which is appropriately modified according to the invention ready for injection into the patient.
- The time for which the aliquot is subjected to the stressors can be from a few seconds to about 60 minutes. It is normally within the time range of from about 0.5-60 minutes. This depends to some extent upon the chosen intensity of the UV irradiation, the temperature and the concentration of and rate at which the oxidizing agent is supplied to the aliquot. Some experimentation to establish optimum times and dosages may be necessary on the part of the operator, once the other stressor levels have been set. Under most stressor conditions, preferred times will be in the approximate range of about 0.5-10 minutes, most preferably 2-5 minutes, and normally around 3 minutes.
- In the practice of one preferred process of the present invention, the suspension of cells may be treated with oxygen/ozone gas mixture and optionally also with UV radiation using an apparatus of the type described in U.S. Pat. No. 4,968,483 Mueller. The suspension is placed in a suitable, sterile, UV-radiation-transmissive container, which is then fitted into the machine. The temperature of the aliquot is adjusted to the predetermined value, e.g. 42.5±1 C, by the use of a suitable heat source such as an IR lamp, and the UV lamps are switched on for a fixed period before the gas flow is applied to the aliquot providing the oxidative stress, to allow the output of the UV lamps to stabilize. The oxygen/ozone gas mixture, of known composition and control flow rate, is applied to the aliquot, for the predetermined duration of 0.5-60 minutes, preferably 1-5 minutes and most preferably about 3 minutes as discussed above. In this way, the suspension is appropriately modified according to the present invention sufficient to achieve the desired effects of alleviation or prevention of GVHD.
- From another aspect, the preferred embodiment of the present invention may be viewed as a process of treating allogeneic T-cells prior to their introduction into a patient, by extracorporeally stressing the T-cells, which comprises subjecting the T-cells to oxidative stress such as exposure to ozone or ozone/oxygen. The treated allogeneic T-cells from the process of the invention have a direct effect on the development and progression of GVHD. The donor T-cells pretreated according to the process of the invention prior to introduction into the host patient, have been modified, so that they no longer mount a deleterious response. Their ability to mount an inflammatory cytokine response has been decreased. For example their ability to secrete IFNγ, TNFα and IL-2, and their proliferative response to standard mitogens has been reduced. Accordingly they no longer react against incompatible systemically distributed host histocompatibility antigens to cause inflammation to any great extent. The allogeneic stem cells administered to the patient can proceed with engraftment with improved chance of success. After a period of time, the treated T-cells largely recover their proliferative ability and immune response functions, but remain relatively unresponsive (tolerant) to differing host histocompatibility antigens.
- The invention is further described, for illustrative purposes, in the following specific examples.
- The spleen of a mammal offers a convenient, accessible source of cells, especially T-cells but also including small quantities of stem cells and is particularly useful in connection with animal models for experimental purposes.
- Experimental testing to obtain indication of the utility of the process of the present invention was conducted using a model of acute GVHD in SCID mice. T-cells from C57B1/6J (B6) mice were intravenously injected into sub-lethally irradiated CB-17 SCID mice. The latter are congenitally lymphopenic and provide a strong stimulus for donor cells due to their complete disparity at the major histocompatibility locus (MHC). The mean survival time of host mice in this model is 14 days. GVHD is characterized by suppression of host hematopoietic recovery from irradiation; expansion of T-cells that use Vβ3 chain to form their T-cell receptor complexes (TCR's); spontaneous secretion of interferon-γ and TNF-α, by donor T-cells, and aberrant localization of donor T-cells to the red pulp areas of the spleen. If donor marrow is co-injected with T-cells, a chronic form of GVHD results.
- Mouse spleen cells from C57B1/6J (B6) mice were suspended to a density of 107/ml in A-MEM, 2ME and 10% fetal calf serum (FCS). The FCS contains cytokines and growth factors. The cell suspension was subjected simultaneously to ultraviolet radiation from UV-C lamps, wavelength 253.7 nm, whilst bubbling through the suspension a gas mixture of 14-15 mcg/ml Iozone/medical grade oxygen, at 42.5° C. The treatment took place for 3 minutes.
- Immediately after the treatment, the cells had a viability of only about 10%.
- The experiment of Example 1 was essentially repeated except that the cells were suspended in 100% FCS. The immediate survival of the cells in this case was 50-60%, indicating that factors present in the FCS have exerted a protective effect on at least some of the cells.
- Murine B6 spleen cells suspended in 100% FCS were subjected to UV-oxidation-heat treatment The cell suspension was subjected simultaneously to ultraviolet radiation from UV-C lamps, wavelength 253.7 nm, whilst bubbling through the suspension a gas mixture of 14-15 mcg/ml ozone/medical grade oxygen, at 42.5° C. The treatment took place for 3 minutes. Varying numbers were injected into sub-lethally irradiated CB-17 SCID mice. Their subsequent behaviour was compared with similar numbers of B6 spleen cells, not subjected to the treatment.
- FIG. 1 is a graphical presentation of the results of these experiments, where the % survival of the animals in each group is plotted as ordinate against days following injection of the treated or untreated cells. At all dosage levels, there is a marked improvement of survival when the treated cells are used as opposed to the untreated cells, demonstrating potential for the process of the invention in alleviating GVHD.
- FIG. 2 of the accompanying drawings is a plot of the number of donor T-cells per spleen against days after GVHD induction, in these same experiments. This shows that the treated donor T-cells survive and expand in number in the host mice, although to a more limited degree than control, untreated B6 T-cells.
- Six days after initiation of GVHD in the mice by injection of the donor cells (treated and untreated), donor T-cells were separated from SCID spleen cells by density gradient centrifugation. Intracellular cytokine staining was performed according to the method of Ferrick, D. A. et. al., NATURE 373 225,257, 1995. The staining was performed on spleen cell suspensions on
day 8 after injection of B6 spleen cells. Cytokine production was determined 4 hours after stimulation in vitro-with PHA ard ionomycin in the presence of brefeldin-A and after gating on CD4+ and CD8+. The results were assessed by intracellular flow cytometry, and the results thereof are depicted in FIG. 3 of the accompanying drawings. The percentage of each cells in each quadrant is recorded. The drawing shows significantly reduced levels of the inflammatory cytokines interferon-=65 (INF) and tissue necrosis factor-α (TNF), lower right quadrants, from the T-cells which had been stressed as described in Example 1, as compared with untreated cells and controls. - Inversion of the normal ratio of CD4+ to CD8+ T-cells (usually approximately 2:1) is known to accompany GVHD. By intracellular cytokine staining techniques following the method of Ferrick et.al.,Nature 373: 255-257, 1995 and using anti-CD4 and CD8-tricolor antibodies, CD4/CD8 ratios were determined. In the untreated donor spleen cells after injection into sub-lethally irradiated mice, the inversion of the normal ratio was confirmed. The initial CD4/CD8 ratios of 1.3±0.2 and 2.2±0.3 decreased to 0.33±0.05 and 0.9±0.1 by day 13 for unstressed B6 and C3H donor T cells, respectively, at a time when many animals were succumbing to GVHD. In contrast, the ratios remained greater than 1 at all times and correlated with the lack of clinical evidence of GVHD when donor cells had been pretreated with the stressors as described in Example 1.
- This example demonstrates the principle of the invention, using oxidative stress alone, provided by hydrogen peroxide, an effective chemical oxidizing agent and representative of many other, perhaps more biologically suitable, chemical oxidizing agents.
- Peripheral human blood mononuclear cells PBMCs, which is a collection of white blood cells comprising about 40% T-cells, were stressed by contact with aqueous solutions of hydrogen peroxide, of various concentrations, for 20 minutes. Their immediate survival was measured, along with their immediate phytohaemagglutinin (PHA) response. Then their survival after 24 hours was measured, followed by their PHA response (tritiated thymidine uptake following mitogenic stimulation with PHA) and cytokine profile after 7 days. The results are given in the following table.
TABLE PHA 24 hr Immediate re- Immediate survival PHA sponse Cytokine Conc. H2O2 survival % % response 7- day Profile 100 μmole/L 80-90 100 2000 + IFN↓ 300 μmoIe/L 80-90 50 2000 + IFN↓ 1 mmole/L 80-90 40 400 + IFN↓ 3 mmole/L 80-90 40 400 + IFN↓ Control 95 95 8575 + IFN↑ - These results indicate that T-cells subjected to oxidative stress alone achieve a decreased proliferative response and decreased inflammatory cytokine production, suitable for use in the present invention.
Claims (22)
1. A process for preparing an allogeneic cell population for administration to a human patient suffering from a bone marrow disorder potentially treatable by bone marrow transplantation, which comprises subjecting, in vitro, a population of donor cells enriched in T-cells to oxidative stress to induce in said T-cells an altered cytokine production profile and a reduced proliferative response.
2. The process of wherein the oxidative stress is imparted by subjection to an ozone/oxygen gaseous mixture.
claim 1
3. The process of wherein the ozone/oxygen gas mixture is bubbled through an aqueous suspension of said T-cell containing population at a rate of from about 0.01-2 liters per minute.
claim 2
4. The process of wherein the ozone/oxygen gas mixture has an ozone content of from about 1.0-100 μg/ml.
claim 3
5. The process of wherein the ozone/oxygen gas mixture is bubbled through an aqueous suspension of said T-cell containing population at a rate of from about 0.05-1.0 liters per minute, the gas mixture having an ozone content of from about 3-70 μg/ml.
claim 2
6. The process of wherein the T-cell containing population is additionally subjected to UV radiation.
claim 3
7. The process of wherein the T-cell containing population is subjected to oxidative stress and UV radiation simultaneously.
claim 6
8. The process of wherein the UV radiation is UV-C.
claim 7
9. The process wherein the time of simultaneous subjection to oxidative stress and UV radiation is from 0.5-60 minutes.
claim 8
10. The process of wherein the time is from 2-5 minutes.
claim 9
11. The process of wherein the T-cell containing population is a human white blood cell fraction obtained from human peripheral blood by leukopheresis.
claim 5
12. The process of wherein the T-cell containing population is a peripheral blood mononuclear cell fraction from human blood.
claim 11
13. The process of wherein the oxidative stress is imparted by addition of a chemical oxidizing agent to a suspension of said T-cell enriched donor cell population.
claim 1
14. The process of wherein the T-cell enriched donor cell population is a peripheral blood mononuclear cell fraction from human blood.
claim 13
15. A process of treating a mammalian patient for alleviation of a bone marrow disorder potentially treatable by bone marrow transplantation, with alleviation of consequentially developed graft versus host disease, which comprising administering to the patient allogeneic hematopoietic stem cells and allogeneic T-cells, at least a portion of said T-cells having been subjected to oxidative stress in vitro, prior to administration to the patient, so as to induce decreased inflammatory cytokine production and a reduced proliferative response therein.
16. The process of wherein the T-cells are administered separately from the stem cells.
claim 15
17. The process of wherein the T-cells consist essentially of peripheral blood mononuclear cells obtained from peripheral human blood.
claim 16
18. The process of or wherein the T-cells have been subjected to oxidative stress by application thereto of a gaseous oxygen/ozone mixture.
claim 16
19. The process of wherein the T-cells have been subjected to oxidative stress by application thereto of a chemical oxidizing agent.
claim 16
20. The process of wherein the T-cells have been additionally subjected to UV radiation, simultaneously with the subjection to oxidative stress.
claim 18
21. A population of mammalian T-cells essentially free of stem cells, said T-cells having been subjected in vitro to oxidative stress so as to induce in said cells a reduced inflammatory cytokine production and a reduced proliferative response.
22. Peripheral blood mononuclear cells obtained from human peripheripheral blood by leukopheresis, said cells having been subjected in vitro to oxidative stress so as to induce in the T-cell component thereof a reduced inflammatory cytokine production and a reduced proliferative response.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/853,755 US20010028879A1 (en) | 1998-07-30 | 2001-05-14 | Inhibition of graft versus host disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2244554 CA2244554A1 (en) | 1998-07-30 | 1998-07-30 | Inhibition of graft versus host disease |
CA2,244,554 | 1998-07-30 | ||
US09/363,678 US6258357B1 (en) | 1998-07-30 | 1999-07-30 | Inhibition of graft versus host disease |
US09/853,755 US20010028879A1 (en) | 1998-07-30 | 2001-05-14 | Inhibition of graft versus host disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/363,678 Division US6258357B1 (en) | 1998-07-30 | 1999-07-30 | Inhibition of graft versus host disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010028879A1 true US20010028879A1 (en) | 2001-10-11 |
Family
ID=4162727
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/363,678 Expired - Fee Related US6258357B1 (en) | 1998-07-30 | 1999-07-30 | Inhibition of graft versus host disease |
US09/853,755 Abandoned US20010028879A1 (en) | 1998-07-30 | 2001-05-14 | Inhibition of graft versus host disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/363,678 Expired - Fee Related US6258357B1 (en) | 1998-07-30 | 1999-07-30 | Inhibition of graft versus host disease |
Country Status (16)
Country | Link |
---|---|
US (2) | US6258357B1 (en) |
EP (1) | EP1100875A2 (en) |
JP (1) | JP2002523332A (en) |
KR (1) | KR20010072095A (en) |
CN (1) | CN1314939A (en) |
AU (1) | AU755630B2 (en) |
BR (1) | BR9912594A (en) |
CA (1) | CA2244554A1 (en) |
CZ (1) | CZ2001316A3 (en) |
EA (1) | EA200100195A1 (en) |
IL (1) | IL141007A0 (en) |
MX (1) | MXPA01001144A (en) |
NO (1) | NO20010490L (en) |
NZ (1) | NZ509387A (en) |
WO (1) | WO2000006703A2 (en) |
ZA (1) | ZA200101614B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265963A1 (en) * | 2003-04-18 | 2004-12-30 | Johnson Howard M. | Inhibitors of autophosphorylation protein kinases |
US8617884B2 (en) | 2002-06-28 | 2013-12-31 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE516133C2 (en) * | 1999-02-25 | 2001-11-19 | Lundblad Leif J I | Use of certain substituted indoloquinoxalins for the preparation of an agent for the protection of tissues, organs and cells during transplantation |
US8147824B2 (en) * | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
CA2324199A1 (en) * | 2000-10-25 | 2002-04-25 | Vasogen Ireland Limited | Chronic lymphocytic leukemia treatment |
CN102302493B (en) * | 2001-07-31 | 2015-08-12 | 健赞股份有限公司 | The method of activation of progenitor cells/stem cell |
US7037900B2 (en) * | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
EP1539929B1 (en) * | 2002-06-28 | 2013-04-10 | Life Technologies Corporation | Methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
WO2007011960A2 (en) * | 2005-07-18 | 2007-01-25 | Advanced Immune Biotechnologies, Inc. | Methods and agents to treat autoimmune diseases |
US20100196327A1 (en) * | 2007-04-11 | 2010-08-05 | Cell Science Systems | Methods for diagnosing biological samples containing stem cells |
WO2009073518A1 (en) * | 2007-11-30 | 2009-06-11 | New York Medical College | Methods of isolating non-senescent cardiac stem cells and uses thereof |
US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
EP2612907A1 (en) * | 2012-01-05 | 2013-07-10 | Taipei Veterans General Hospital | Preparation of cell transplant |
RU2508924C1 (en) * | 2013-02-21 | 2014-03-10 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" | Method for prevention and treatment of renal graft rejection |
JP7445946B2 (en) * | 2019-06-12 | 2024-03-08 | 国立大学法人九州大学 | Property change method and plasma generation device |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
WO1996037208A1 (en) | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
DE69609943T2 (en) * | 1996-03-29 | 2001-04-12 | Procter & Gamble | Assessment method for disposable absorbent structures |
-
1998
- 1998-07-30 CA CA 2244554 patent/CA2244554A1/en not_active Abandoned
-
1999
- 1999-07-30 EP EP19990936202 patent/EP1100875A2/en not_active Withdrawn
- 1999-07-30 EA EA200100195A patent/EA200100195A1/en unknown
- 1999-07-30 IL IL14100799A patent/IL141007A0/en unknown
- 1999-07-30 AU AU51433/99A patent/AU755630B2/en not_active Ceased
- 1999-07-30 MX MXPA01001144A patent/MXPA01001144A/en unknown
- 1999-07-30 CN CN99810240A patent/CN1314939A/en active Pending
- 1999-07-30 BR BR9912594A patent/BR9912594A/en not_active IP Right Cessation
- 1999-07-30 KR KR1020017001235A patent/KR20010072095A/en not_active Application Discontinuation
- 1999-07-30 WO PCT/CA1999/000706 patent/WO2000006703A2/en active Search and Examination
- 1999-07-30 JP JP2000562485A patent/JP2002523332A/en active Pending
- 1999-07-30 CZ CZ2001316A patent/CZ2001316A3/en unknown
- 1999-07-30 NZ NZ50938799A patent/NZ509387A/en unknown
- 1999-07-30 US US09/363,678 patent/US6258357B1/en not_active Expired - Fee Related
-
2001
- 2001-01-29 NO NO20010490A patent/NO20010490L/en not_active Application Discontinuation
- 2001-02-27 ZA ZA200101614A patent/ZA200101614B/en unknown
- 2001-05-14 US US09/853,755 patent/US20010028879A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617884B2 (en) | 2002-06-28 | 2013-12-31 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
US20040265963A1 (en) * | 2003-04-18 | 2004-12-30 | Johnson Howard M. | Inhibitors of autophosphorylation protein kinases |
US7189694B2 (en) * | 2003-04-18 | 2007-03-13 | University Of Florida Research Foundation, Inc. | Inhibitors of autophosphorylation protein kinases |
Also Published As
Publication number | Publication date |
---|---|
IL141007A0 (en) | 2002-02-10 |
MXPA01001144A (en) | 2002-04-24 |
WO2000006703A3 (en) | 2000-05-04 |
WO2000006703A2 (en) | 2000-02-10 |
AU5143399A (en) | 2000-02-21 |
EA200100195A1 (en) | 2001-10-22 |
ZA200101614B (en) | 2002-01-02 |
CN1314939A (en) | 2001-09-26 |
KR20010072095A (en) | 2001-07-31 |
NO20010490D0 (en) | 2001-01-29 |
CA2244554A1 (en) | 2000-01-30 |
NZ509387A (en) | 2002-10-25 |
NO20010490L (en) | 2001-03-29 |
AU755630B2 (en) | 2002-12-19 |
US6258357B1 (en) | 2001-07-10 |
EP1100875A2 (en) | 2001-05-23 |
BR9912594A (en) | 2002-04-23 |
JP2002523332A (en) | 2002-07-30 |
CZ2001316A3 (en) | 2001-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6258357B1 (en) | Inhibition of graft versus host disease | |
Besnier et al. | TREATMENT OF GRAFT-VERSUS-HOST DISEASE BY EXTRACORPOREAL PHOTOCHEMOTHERAPY: A Pilot Study: 1 | |
Johnson et al. | Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets | |
Mastino et al. | Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice | |
US6733748B2 (en) | Chronic lymphocytic leukemia treatment | |
US6669965B2 (en) | Method of treating atherosclerosis | |
US20030108536A1 (en) | Inhibition of graft versus host disease | |
CA2356882A1 (en) | Graft versus host disease | |
Shen et al. | Curative effect of split low dosage total-body irradiation on mice infected with the polycythemia-inducing strain of the Friend virus complex | |
Yoshioka et al. | The role of tumor-specific Lyt-1+ 2− T cells in eradicating tumor cells in vivo: II. Lyt-1+ 2− T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells | |
CA2398401A1 (en) | Improved inhibition of graft versus host disease | |
Rosenfeld et al. | Ex vivo purging of allogeneic marrow with L-leucyl-L-leucine methyl ester: a phase I study | |
Ishizu et al. | Immune-mediated regression of ‘metastatic’neuroblastoma in the liver | |
Sheng-Tanner et al. | Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors | |
US20030157114A1 (en) | Treatment of autoimmune diseases | |
US20020090360A1 (en) | Inflammatory cytokine secretion inhibition | |
Hoon et al. | Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor | |
Szebeni et al. | Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning | |
Collins et al. | Characterization of a low molecular weight suppressor of lymphocyte proliferation from guinea pig 12C leukemia cells | |
WO2004024171A1 (en) | Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine) | |
Kasakura | Recent developments in basic and clinical hematopoietic stem cell transplantation | |
US20020090359A1 (en) | Transforming growth factor regulation | |
WO2002045723A2 (en) | Inflammatory cytokine secretion inhibition with modified mammalian blood | |
CA2430937A1 (en) | Inflammatory cytokine secretion inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |